Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Vermaat, Joost S. P." or (type any "bookEditor journalEditor issueEditor" and editor="Ver...

Add to list
- Journal Article
- A1
- open access
The association between patient characteristics and the efficacy and safety of selinexor in diffuse large B-cell lymphoma in the SADAL study

Josee M. Zijlstra, George Follows, Rene-Olivier Casasnovas, Joost S. P. Vermaat, Nagesh Kalakonda, Sylvain Choquet, Brian Hill, Catherine Thieblemont, Federica Cavallo, Fatima De la Cruz, et al.

(2022) CANCERS. 14(3).
Add to list
Comparison of the effectiveness and safety of the oral selective inhibitor of nuclear export, selinexor, in diffuse large B cell lymphoma subtypes

Rene-Olivier Casasnovas, George Follows, Josee M. Zijlstra, Joost S. P. Vermaat, Nagesh Kalakonda, Sylvain Choquet, Eric Van den Neste, Brian Hill, Catherine Thieblemont, Federica Cavallo, et al.

(2022) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 22(1). p.24-33
Add to list
- Journal Article
- A1
- open access
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

Jatin Shah, Sharon Shacham, Michael Kauffman, Patrick Daniele, Dimitrios Tomaras, Gabriel Tremblay, Rene-Olivier Casasnovas, Marie Maerevoet, Josee Zijlstra, George Follows, et al.

(2021) FUTURE ONCOLOGY. 17(11). p.1295-1310
Add to list
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL) : a single-arm, multinational, multicentre, open-label, phase 2 trial

Nagesh Kalakonda, Marie Maerevoet, Federica Cavallo, George Follows, Andre Goy, Joost S. P. Vermaat, Olivier Casasnovas, Nada Hamad, Josee M. Zijlstra, Sameer Bakhshi, et al.

(2020) LANCET HAEMATOLOGY. 7(7). p.E509-E522
Add to list
A phase 2b study of selinexor in patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Nagesh Kalakonda, Federica Cavallo, George Follows, Andre Goy, Joost S. P. Vermaat, Olivier Casasnovas, Orly Lavee, Marie Maerevoet, Josee Zijlstra, Sameer Bakhshi, et al.

(2019) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 19. p.S248-S249

Academic Bibliography

The association between patient characteristics and the efficacy and safety of selinexor in diffuse large B-cell lymphoma in the SADAL study

Comparison of the effectiveness and safety of the oral selective inhibitor of nuclear export, selinexor, in diffuse large B cell lymphoma subtypes

Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL) : a single-arm, multinational, multicentre, open-label, phase 2 trial

A phase 2b study of selinexor in patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Contents

Support

Contact